Somatostatin in diabetic retinopathy

Pediatric Endocrinology Reviews

Volumn 1, Issue SUPPL. 3, 2004, Pages 518-524

  Croxen, Rebecca ^a,b   Baarsma, G S ^b   Kuijpers, R W A M ^a   Van Hagen, P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROTTERDAM EYE HOSPITAL   (Netherlands)

Author keywords

Diabetic retinopathy; Growth hormone; IGF 1; Octreotide; Somatostatin; VEGF

Indexed keywords

L 779976; L 796778; OCTREOTIDE; SEGLITIDE; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DIABETIC RETINOPATHY; DISEASE COURSE; HUMAN; LASER COAGULATION; NONHUMAN; RETINA; VITRECTOMY;

ANIMALS; DIABETIC RETINOPATHY; HUMANS; OCTREOTIDE; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 13444312073     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102(4):520-526
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102(4):527-532
3. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996;97(12):2883-2890
4. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102(1):7-16
5. Poulsen JE. The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes 1953;2:7-12
6. Sharp PS, Fallon TJ, Brazier OJ, Sandler L, Joplin GF, Kohner EM. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987;30(4):199-207
7. Sonksen PH, Russell-Jones D, Jones RH. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future? Horm Res 1993;40(1-3):68-79
8. Fainstein Day P, Fagin JA, Vaglio RM, Litwak LE, Picasso MF, Gutman RA. Growth hormone-insulin-like growth factor-I axis in adult insulin-dependent diabetic patients: evidence for central hypersensitivity to growth hormone-releasing hormone and peripheral resistance to growth hormone. Horm Metab Res 1998;30(12):737-742
9. Passa R, Rousselie F, Gauville C, Canivet J. Retinopathy and plasma growth hormone levels in idiopathic hemochromatosis with diabetes. Diabetes 1977;26(2):113-120
10. Merimee TJ. A follow-up study of vascular disease in growth-hormone- deficient dwarfs with diabetes. N Engl J Med 1978;298(22):1217-1222
11. Koller EA, Green L, Gertner JM, Bost M, Mozowski SN. Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients. J Clin Endocrinol Metab 1998;83(7):2380-2383
12. Rymaszewski Z, Cohen RM, Chomczynski P. Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. Proc Natl Acad Sci USA 1991; 88: 617-621
13. Herrington J, Carter-Su C. Signalling pathways activated by the growth hormone receptor. Trends Endocrinol Metab 2001;12(6):252-257
14. Bichell DP, Kikuchi K, Rotwein P. Growth hormone rapidly activates insulin-like growth factor I gene transcription in vivo. Mol Endocrinol 1992;6(11):1899-1908
15. D'Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C. Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A 1984;81(3):935-939
16. Rotwein P, Thomas M J, Harris DM, Gronowski AM, LeStunff C. Nuclear actions of growth hormone: an in vivo perspective. J Anim Sci 1997;75:11-19
17. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med 1983;309(9):527-530
18. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metabolism 1989;38(6):586-589
19. Hellstrom A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L, Savage M, Svensson E, Smith L, Weinberger D, Albertsson Wikland K, Laron Z. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002;87(7):3413-3416
20. Grant, MB, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes 1986;35:416-420
21. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, Kahn CR. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 2003;111(12):1835- 1842
22. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5(12):1390-1395
23. Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, George M, Llombart C, Casellas A, Costa C, Bosch A, Bosch F. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 2004;113(8):1149-1157
24. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg MA, D'Amato RJ, Adamis AP. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 1997;46(10):1619-1626
25. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22(1):1-29
26. Beilmann M, Birk G, Lenter MC. Human primary co-culture angiogenesis assay reveals additive stimulation and different angiogenic properties of VEGF and HGF. Cytokine 2004;26(4):178-185
27. Kevil CG, Payne DK, Mire E, Alexander JS. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 1998;273(24):15099-15103
28. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118(4):445-450
29. Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy Br J Ophthalmol 1998;82(5):561-568
30. Simpson DA, Murphy GM, Bhaduri T, Gardiner TA, Archer DB, Stitt AW. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem Biophys Res Commun 1999; 262(2):333-340
31. Smith G, McLeod D, Foreman D, Boulton M: Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy. Br J Ophthalmol 1999;83(4):486-489
32. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 2000;184(3):301-310
33. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103(11):1820-1828
34. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LEH. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:104 57-10461
35. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LES. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996;93:4851-4856
36. Ohno-Matsui K, Hirose A, Yamamot S, Saikia J, Okamoto N, Gehlbac P, Duh EJ, Hackett S, Chang M, Bok D, Zack D J, Campochiaro PA. Inducible expression of vascular endothelial growth factor in adult mice causes proliferative retinopathy and retinal detachment. Am J Pathol 2002; 160:711-719
37. Watanabe D, Takagi H, Suzuma K, Suzuma I, Oh H, Ohashi H, Kemmochi S, Uemura A, Ojima T, Suganami E, Miyamoto N, Sato Y, Honda Y. Transcription factor Ets-1 mediates ischemia and vascular endothelial growth factor-dependent retinal neovascularization. Am J Pathol 2004;164(5):1827-1835
38. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999;274(22):15732-15739
39. Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, Yancopoulos G, Campochiaro PA. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 2000;184(3):275-284
40. Hammes HP, Lin J, Wagner P, Feng Y, Vom Hagen F, Krzizok T, Renner O, Breier G, Brownlee M, Deutsch U. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004;53(4):1104-1110
41. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179(68):77-79
42. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20(3):157-198
43. Tornqvist, K, Ehinger, B. Peptide immunoreactive neurons in the human retina. Invest Ophthalmol Vis Sci 1988;29:680-686
44. Mitrofanis, J, Robinson, SR, Provis, JM. Somatostatinergic neurons of the developing human and cat retinae Neurosci Lett 1989,104:209-216
45. Li, HB, Lam, DM. Localization of neuropeptide-immunoreactive neurons in the human retina. Brain Res 1990;522:30-36
46. Jen, PY, Li, WW, Yew, DT. Immunohistochemical localization of neuropeptide Y and somatostatin in human fetal retina. Neuroscience 1994;60:727-735
47. Vasilaki A, Papadaki T, Notas G, Kolios G, Mastrodimou N, Hoyer D, Tsilimbaris M, Kouromalis E, Pallikaris, Thermos, K. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. Invest Ophthalmol Vis Sci 2004;45(5):1499-1505
48. van Hagen PM, Baarsma GS, Mooy CM, Ercoskan EM, ter Averst E, Hofland LJ, Lamberts SW, Kuijpers RW. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 2000;143 (Suppl 1):S43-51
49. Klisovic DD, O'Dorisio MS, Katz, SE, Sall JW, O'Dorisio TM, Craig E, Lubow M. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and lmmunohistochemical study. Invest Ophthalmol Vis Sci 2001;42(10):2193-2201.
50. Pless J. Chemistry and pharmacology of Sandostatin. Z Gastroenterol 1990;28(Suppl 2):4-7
51. Higgins RD, Yan Y, Schrier BK. Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res 2002;74(5):553-559
52. Smith LEH, Kopchick, JJ, Chen W, Knapp J, Kinose F, Daley, D, Foley, E, Smith RG, Schaeffer JM. Essential role of growth hormone in ischemia-induced retinal neovascularisation. Science 1997;276:1706-1709
53. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000;268(2):567-571
54. Baldysiak-Figiel, A Lang GK, Kampmeier J, Lang GE: Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. J Endocrinol 2004;180(3):417-424
55. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-1 and bFGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularisation. Regul Pept 1993;48:267-278
56. Neel BG, Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 1997;9:193-204
57. Bousquet C, Delesque N, Lopez F, Saint-Laurent N, Esteve JP, Bedecs K, Buscail L, Vayesse N, Susini C. Sst2 somatostatin receptor mediates negative regulation of insulin receptor signalling through the tyrosine phosphatase SHP-1. J Biol Chem 1998;273:7099-7106
58. Spoerri PE, Caballero S, Wilson SH, Shaw LC, Grant MB. Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest Ophthalmol Vis Sci 2003;44(1):365-369
59. Lee HK, Suh Ki, Koh CS, Min HK, Lee JH, Chung H. Effect of SMS 201-995 in rapidly progressive diabetic retinopathy. Diabetes Care 1988;11(5):441-443
60. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, Vague P. Stabilization of severe proliferate diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab 1992;18(6):438-444
61. Kirkegaard C, Norgaard K, Snorgaard O, Bek T, Larsen M, Lund-Andersen H. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenh) 1990;122(6):766-772
62. Grant MB, Mames R, Cooper R, Caballero S, Fitzgerald C. Octreotide does not prevent progression of diabetic retinopathy (Abstract). Invest Ophthalmol Vis Sci 1996;37:S958
63. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, Estes KS. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000;23(4):504-509
64. Gehrs KM. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Response to Grant et al. (Letter). Diabetes Care 2000;24:182
65. Grant MB: Efficacy of Octreotide in the Therapy of Severe Nonproliferative and Early Proliferative Diabetic Retinopathy: A Randomized Controlled Study. Response to Gehrs. Diabetes Care 2000;24:182-183
66. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Norm Metab Res 2001;33(5):300-306
67. Kuijpers, RW, Baarsma S, van Hagen P. Treatment of cystoid macular edema with octreotide (Letter). N Eng J Med 1998;338:624-626